WASHINGTON: A fresh tariff timeline unveiled by President Donald Trump on generic pharmaceutical imports is set to reverberate most sharply through one relationship in particular: the deep trade partnership between the United States and India, the world’s largest supplier of generic medicines to the American market.
Indian pharmaceutical manufacturers currently supply roughly half of all generic medicines consumed in the United States, and the American market accounts for close to a third of India’s total pharma exports, according to industry data cited in coverage of the announcement.
That scale of exposure means the new tariff schedule — even with its two-year grace period — has already drawn close attention from Indian drug makers and market watchers, given how central US sales are to their revenue base. The policy adds a fresh layer of uncertainty to a trade relationship that has been under strain over other tariff disputes in recent months, and it raises the stakes for Indian firms weighing whether to accelerate US manufacturing investments or absorb the cost of eventual tariffs.
In a post on Truth Social on Tuesday, Trump laid out a phased tariff structure for generic drugs entering the US.
Generic imports will keep facing a zero percent tariff through August 1, 2028 — two years from the policy’s effective date — after which a 100 percent tariff kicks in for one year, rising to 200 percent thereafter.
Trump framed the schedule as a “penalty” mechanism aimed at pushing manufacturers to build production facilities on US soil within the transition window, rather than continue relying on overseas plants.
He drew a clear line between this policy and the administration’s approach to branded, patented drugs, which he said would remain unchanged given its success so far.
According to the Fox Business report on the announcement, the White House said the new tariffs on generics will be implemented under Section 232 trade authority — the same legal basis used for the administration’s earlier tariffs on branded pharmaceuticals imposed in April.
Trump also pointed to what he described as an unprecedented wave of new pharmaceutical facility construction already underway across the US, framing the tariff timeline as reinforcing a shift already in motion.
Why It Matters
Generic drugs make up close to 90 percent of all prescriptions filled in the United States, making the policy consequential for the broader US healthcare system as well as for exporting countries.
The move follows a string of earlier actions targeting the pharmaceutical sector, including the 100 percent tariff the administration placed on branded drugs starting in October 2025, alongside a “most-favored-nation” pricing push that has led more than a dozen major drugmakers — including Eli Lilly, Pfizer, and Novo Nordisk — to strike agreements lowering US drug prices in exchange for a multi-year tariff exemption.
For India specifically, the two-year runway offers breathing room but not certainty. Indian pharmaceutical companies will now face a choice: commit capital to building or expanding US manufacturing plants ahead of the 2028 deadline, or risk a steep cost disadvantage once the tariff escalation begins. Analysts are expected to watch closely for signs of accelerated US investment announcements from major Indian drugmakers in the coming months as the industry weighs its response.
